Monoclonal Antibodies Market
Increased usage of Monoclonal Antibodies in the treatment of Many Cancers to push Market Growth
Monoclonal Antibodies Market by Production Type, Source, Application, End-User & Region | Forecast 2022 to 2032
Monoclonal Antibodies Market Snapshot (2022 to 2032)
[286 Pages Report] The global monoclonal antibodies market was valued at US$ 186 Billion in 2021 and is projected to exhibit a CAGR of 12% from 2022 to 2032. The rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and others is increasing the demand for biologics, which is anticipated to serve as a key factor driving the monoclonal antibodies (mAbs) market. Similarly, increasing applications of mAb therapies for targeted therapies and rising awareness about such therapies amongst patients and physicians is expected to significantly contribute toward the market growth.
Increased usage of Monoclonal antibodies in the treatment of many cancers in industrialized countries, is leading to a rapid rise in the worldwide monoclonal antibody market. As per the GLOBOCAN 2020 research, there were 19.3 million new cancer diagnoses and approximately 10 million cancer-related deaths worldwide.
In order to control the rising number, research & development activities in the market are creating new opportunities. New gene-based therapy, new research related to the application of monoclonal antibodies in treating other deadly diseases, such as COVID-19, disease diagnostics, and treatment of other diseases, including auto-immune, viral disease treatment, and government approval of new antibodies may all contribute to the market's growth.
For instance, Union Chimique Belge (UCB) signed a license agreement with Roche and Genentech in July 2020 for the manufacturing and commercialization of UCB0107, a potent monoclonal antibody for the treatment of progressive supranuclear palsy (PSP) and Alzheimer's disease, but it is still being studied.
|
Data Points |
Key Statistics |
|
Estimated Base Year Value (2021) |
US$ 186 Billion |
|
Expected Market Value (2022) |
US$ 208.32 Billion |
|
Anticipated Forecast Value (2032) |
US$ 647.01 Billion |
|
Projected Growth Rate (2022 to 2032) |
12% CAGR |
Let us know your requirement to get
100% FREE customization
2017-2021 Monoclonal Antibodies Demand Analysis vs. Forecast 2022-2032
The global demand for Monoclonal Antibodies is projected to increase at a CAGR of 12% during the forecast period between 2022 and 2032, reaching a total of US$ 647.01 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6.1%.
Human mAbs offer efficient modulation in effector functions and are less immunogenic as compared to chimeric or humanized mAbs. Such antibodies can be produced through the use of phage display and hybridoma technologies in transgenic mice. As a result, with recent technological progress in genetic engineering, the production of fully human mAbs is anticipated to gain traction in the near future.
Humanized mAbs are expected to reveal the fastest CAGR in the forecast period due to their widespread use against a broad range of target antigens such as cancer cells, immunosuppression, and immunomodulatory molecules. Demand for such antibodies is also supported by their lower immunogenicity as compared to chimeric mAbs. However, these antibodies are more immunogenic as compared to human mAbs, which may restrict the market growth.
Which are Some Prominent Drivers of the Monoclonal Antibodies Market?
Extensive Uptake during the Pandemic Crisis for Developing Drugs provided a Major Boost in past years
The COVID-19 pandemic has increased the market expansion prospects by fueling the development of several mAbs directed against the SARS-CoV-2 virus. As mAbs represent a promising alternative for the mitigation of COVID-19 due to their safety and effectiveness, several such antibodies have attained emergency use authorizations (EUA) from the U.S. FDA. For instance, in February 2022, the U.S. FDA granted a EUA to Eli Lilly’s bebtelovimab for the treatment of COVID-19 patients that are at risk of developing severe disease or who may need hospitalization.
In addition, the U.S. Department of Health and Human Services announced the distribution of at least 600,000 free bebtelovimab courses, along with an optional purchase of 500,000 additional doses in the future, thus creating new opportunities for growth of mAbs/Key advantages offered by mAb therapies over previous therapies in terms of specificity, effectiveness, and ease of delivery have led to numerous new product launches and approvals in this domain. Over 100 mAb products have been approved by the US FDA and the scope of therapeutic mAb applications is expected to grow further due to the development of antibody fragments, antibody derivatives, and bispecific antibodies that offer advanced treatment options.
Increased Number of Strategic Initiatives Presenting Lucrative Opportunities for Monoclonal Antibodies
The market is also favored by the strategic initiatives undertaken by key players for the development and marketing of mAb products. For instance, in October 2021, T-Cure Bioscience, Inc. collaborated with Atlas Antibodies AB for the production and supply of CT83 mAbs.
Similarly, in January 2022, Ono Pharmaceutical Co., Ltd. and Neurimmune AG collaborated on the creation of mAb drugs against new therapeutic targets for neurodegenerative diseases. Such initiatives are expected to open new growth opportunities and positively affect market growth.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Monoclonal Antibodies Market?
High Development Costs of Monoclonal Antibodies Hindering Growth
High costs associated with the development of mAbs and the resultant increase in prices for mAb therapeutics can impede market growth in the near future. For instance, COVID-19 treatment mAbs such as Regeneron’s REGEN-COV (casirivimab and imdevimab), and GlaxoSmithKline & Vir Biotechnology’s sotrovimab cost around USD 1,250 and USD 2,100 per infusion, respectively. Such high drug prices can limit access to mAb therapies for large patient populations in developing countries and restrict mAbs adoption.
Country-Wise Insights
What Makes North America the Largest Market for Monoclonal Antibodies?
Expansion of the Healthcare Sector in the U.S. Will Drive the Adoption of Monoclonal Antibodies
North America recorded the largest market share of 46.2% in 2021 due to the presence of a highly developed healthcare infrastructure, high patient awareness, and growth in cancer research prospects, among other factors.
Moreover, increasing government expenditure for cancer research and the presence of key players such as Pfizer Inc., Amgen, Inc., and Merck & Co., among others, are expected to boost market growth.
Why is Asia Pacific Considered a Lucrative Region for the Monoclonal Antibodies Market?
Increasing Medical Tourism in Asia Pacific is Spurring Demand for Monoclonal Antibodies
Asia Pacific region is projected to exhibit the fastest growth rate in the forecast period due to the increasing disposable income, availability of a large patient pool for mAb cancer therapeutics, and rising focus on healthcare.
Countries such as India and China offer attractive investment opportunities for clinical research and are anticipated to positively drive research and development prospects for mAbs.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-wise Insights
By Production Type, Which Monoclonal Antibody is Driving Market Growth?
In-vivo Production Type is expected to grow at a Significant Rate
In vivo production held the largest market share in 2021 due to its economic viability in long production runs and lower propensity for contamination with foreign antigens. In addition, the availability of serum-free culture media and semi-permeable membrane-based systems has increased the feasibility of biomanufacturing operations and is likely to accelerate segment growth. However, the production type is limited by variations in hybridoma characteristics that can lead to the denaturation or inactivation of antibodies and restrict segment growth.
In vivo production type is expected to grow at a significant rate in the forecast period due to its highly cost-effective production as compared to in vitro techniques and its ability to produce a high concentration of mAbs. These mAbs are used in the diagnostic industry, wherein cost considerations are of prime importance, and optimization of in vivo procedures can be done to increase the secretion of mAbs.
Which End User Shows Higher Implementation in Monoclonal Antibodies Market?
Demand for Monoclonal Antibodies in Hospitals to Gain Traction
The hospital end-use segment held the largest market share of 40.8% in 2021 due to the increasing adoption of mAbs for cancer treatment at hospitals. Rising healthcare expenditure across the world, increasing patient awareness levels, and availability of advanced hospital infrastructure in developed countries are factors expected to result in the dominance of the segment during the forecast period.
Specialty centers accounted for a significant market share in 2021 due to the increasing government support in recent years. For instance, the National Cancer Institute’s Cancer Centers Program is establishing standards for transdisciplinary cancer centers focused on the prevention, diagnosis, and treatment of various types of cancers. Such initiatives are expected to positively affect segment growth.
Which Application of Monoclonal Antibodies is Expected to Drive the Market?
Oncology Segment to account for Dominant Application of Monoclonal Antibodies
The oncology segment dominated the applications market for mAbs and accounted for 50.1% of the market value in 2021. This can be attributed to the high number of regulatory approvals for mAbs aimed at cancer treatment. The surge in the incidence of cancer is a key factor anticipated to drive the growth of mAbs therapeutics as these can have minimal adverse effects as compared to other drugs and chemotherapy interventions. Currently, available mAb therapeutics include those targeted against non-small cell lung, brain tumor, ovarian, breast, gastric, melanoma, colorectal, Hodgkin’s lymphoma, and others.
Applications of mAbs for the treatment of autoimmune diseases are projected to grow at a lucrative rate due to the increasing prevalence of autoimmune conditions such as rheumatoid arthritis. Furthermore, with growth in the number of cytokine proteins identified in inflammatory pathways that can be targeted for disease mitigation, applications of mAbs in this domain are anticipated to witness growth.
The Start-Up Ecosystem: How Key Players are Opening Frontiers for Future Growth?
Some of the start-ups in the monoclonal antibodies market include-
- The US-based start-up Aridis Pharmaceuticals develops monoclonal antibody discovery platforms for tackling antibiotic-resistant infections. These platforms find and recover B-cells from individuals who have survived antibiotic-resistant infections. Their development pipeline includes drugs targeting staphylococcus aureus, pseudomonas aeruginosa, as well as Acinetobacter baumannii infections.
- French start-up Igyxos is developing a monoclonal antibody-based treatment for female and male infertility. The startup designs the antibody to potentiate the bioactivity of endogenous and exogenous gonadotropins. In addition, the solution induces ovulation in women and regulates spermatogenesis in men by bio-activating gonadotrophins.
- The US-based start-up Yurogen Biosystems is developing humanized mAbs. The startup’s single-cell-based monoclonal antibody (SMab) platform produces mAbs from different host species such as rabbits, monkeys, and humans. The startup offers antibody humanization services for many different kinds of mAbs.
Market Competition
Key players in the Monoclonal Antibodies market are Novartis AG; Pfizer Inc; GlaxoSmithKline plc; Amgen Inc.; Merck & Co., Inc.; Daiichi Sankyo Company, Limited; Abbott Laboratories; AstraZeneca plc; Eli Lilly And Company; Johnson & Johnson Services, Inc. and many more.
- In November 2021, Bristol-Myers Squibb Company received the US Food and Drug Administration approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) combined with limited chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer. Patients with squamous or non-squamous illness, independent of PD-L1 expression, are eligible for the treatment. 1 The FDA's Real-Time Oncology Examine (RTOR) pilot program was used to review this application, which aims to ensure that safe and effective medicines are offered to patients as soon as feasible.
- In March 2022, Sanofi S.A. and Blackstone Life Sciences entered a collaboration for accelerating the development of a subcutaneous formulation of Sarclisa mAb for the treatment of patients with multiple myeloma.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2022 |
US$ 208.32 Billion |
|
Market Value in 2032 |
US$ 647.01 Billion |
|
Growth Rate |
CAGR of 12% from 2022 to 2032 |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2017 to 2021 |
|
Forecast Period |
2022 to 2032 |
|
Quantitative Units |
Revenue in US$ Billion and CAGR from 2022 to 2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Monoclonal Antibodies Market Industry Survey
Monoclonal Antibodies Market by Production Type:
- In Vivo
- In Vitro
Monoclonal Antibodies Market by Source Type:
- Murine
- Chimeric
- Humanized
- Human
Monoclonal Antibodies Market by End User:
- Hospitals
- Specialty Centers
- Others
Monoclonal Antibodies Market by Application:
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Neurological Diseases
- Others
Monoclonal Antibodies Market by Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Frequently Asked Questions
What is the anticipated growth of the market Monoclonal Antibodies until 2032?
FMI projects the global Monoclonal Antibodies market to expand at a 12% value CAGR by 2032.
What is the estimated market value of the Monoclonal Antibodies market expected in 2022?
The global Monoclonal Antibodies market is estimated at a market value of US$ 208.32 Billion.
What is the estimated market value of the Monoclonal Antibodies market expected in 2032?
The global Monoclonal Antibodies market is expected to garner a market value of US$ 647.01 Billion.
Which region is forecast to be the most lucrative for Monoclonal Antibodies market growth?
FMI has projected North America to be one of the key regions for the Monoclonal Antibodies market, with the US expected to account for over 46.2% of the North American market during the forecast period.
Which are some prominent Monoclonal Antibodies manufacturers?
Novartis AG; Pfizer Inc; GlaxoSmithKline plc; Amgen Inc.; Merck & Co., Inc. are some prominent Monoclonal Antibodies manufacturers.
Which Source of Monoclonal Antibodies is expected to Account for the Largest Share in the Forecast Period 2022 to 2032?
The human source type held the largest share and accounted for 54.07% of the market value in 2021.
Table of Content
1. Executive Summary | Monoclonal Antibodies Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Source Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Source Type, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Source Type, 2022 to 2032 5.3.1. Murine 5.3.2. Chimeric 5.3.3. Humanized 5.3.4. Human 5.4. Y-o-Y Growth Trend Analysis By Source Type, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Source Type, 2022 to 2032 6. Global Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Production Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Production Type, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Production Type, 2022 to 2032 6.3.1. In Vivo 6.3.2. In Vitro 6.4. Y-o-Y Growth Trend Analysis By Production Type, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By Production Type, 2022 to 2032 7. Global Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Application, 2017 to 2021 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2022 to 2032 7.3.1. Oncology 7.3.2. Autoimmune Diseases 7.3.3. Infectious Diseases 7.3.4. Neurological Diseases 7.3.5. Others 7.4. Y-o-Y Growth Trend Analysis By Application, 2017 to 2021 7.5. Absolute $ Opportunity Analysis By Application, 2022 to 2032 8. Global Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End-use 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By End-use, 2017 to 2021 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-use, 2022 to 2032 8.3.1. Hospitals 8.3.2. Specialty Centers 8.3.3. Others 8.4. Y-o-Y Growth Trend Analysis By End-use, 2017 to 2021 8.5. Absolute $ Opportunity Analysis By End-use, 2022 to 2032 9. Global Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. Asia Pacific 9.3.5. Middle East & Africa (MEA) 9.4. Market Attractiveness Analysis By Region 10. North America Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. The US. 10.2.1.2. Canada 10.2.2. By Source Type 10.2.3. By Production Type 10.2.4. By Application 10.2.5. By End-use 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Source Type 10.3.3. By Production Type 10.3.4. By Application 10.3.5. By End-use 10.4. Key Takeaways 11. Latin America Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Source Type 11.2.3. By Production Type 11.2.4. By Application 11.2.5. By End-use 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Source Type 11.3.3. By Production Type 11.3.4. By Application 11.3.5. By End-use 11.4. Key Takeaways 12. Europe Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. The UK 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Source Type 12.2.3. By Production Type 12.2.4. By Application 12.2.5. By End-use 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Source Type 12.3.3. By Production Type 12.3.4. By Application 12.3.5. By End-use 12.4. Key Takeaways 13. Asia Pacific Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.1.4. Singapore 13.2.1.5. Thailand 13.2.1.6. Indonesia 13.2.1.7. Australia 13.2.1.8. New Zealand 13.2.1.9. Rest of Asia Pacific 13.2.2. By Source Type 13.2.3. By Production Type 13.2.4. By Application 13.2.5. By End-use 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Source Type 13.3.3. By Production Type 13.3.4. By Application 13.3.5. By End-use 13.4. Key Takeaways 14. MEA Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Source Type 14.2.3. By Production Type 14.2.4. By Application 14.2.5. By End-use 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Source Type 14.3.3. By Production Type 14.3.4. By Application 14.3.5. By End-use 14.4. Key Takeaways 15. Key Countries Monoclonal Antibodies Market Analysis 15.1. U.S. 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2021 15.1.2.1. By Source Type 15.1.2.2. By Production Type 15.1.2.3. By Application 15.1.2.4. By End-use 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2021 15.2.2.1. By Source Type 15.2.2.2. By Production Type 15.2.2.3. By Application 15.2.2.4. By End-use 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2021 15.3.2.1. By Source Type 15.3.2.2. By Production Type 15.3.2.3. By Application 15.3.2.4. By End-use 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2021 15.4.2.1. By Source Type 15.4.2.2. By Production Type 15.4.2.3. By Application 15.4.2.4. By End-use 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2021 15.5.2.1. By Source Type 15.5.2.2. By Production Type 15.5.2.3. By Application 15.5.2.4. By End-use 15.6. The UK 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2021 15.6.2.1. By Source Type 15.6.2.2. By Production Type 15.6.2.3. By Application 15.6.2.4. By End-use 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2021 15.7.2.1. By Source Type 15.7.2.2. By Production Type 15.7.2.3. By Application 15.7.2.4. By End-use 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2021 15.8.2.1. By Source Type 15.8.2.2. By Production Type 15.8.2.3. By Application 15.8.2.4. By End-use 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2021 15.9.2.1. By Source Type 15.9.2.2. By Production Type 15.9.2.3. By Application 15.9.2.4. By End-use 15.10. China 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2021 15.10.2.1. By Source Type 15.10.2.2. By Production Type 15.10.2.3. By Application 15.10.2.4. By End-use 15.11. Japan 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2021 15.11.2.1. By Source Type 15.11.2.2. By Production Type 15.11.2.3. By Application 15.11.2.4. By End-use 15.12. South Korea 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2021 15.12.2.1. By Source Type 15.12.2.2. By Production Type 15.12.2.3. By Application 15.12.2.4. By End-use 15.13. Singapore 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2021 15.13.2.1. By Source Type 15.13.2.2. By Production Type 15.13.2.3. By Application 15.13.2.4. By End-use 15.14. Thailand 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2021 15.14.2.1. By Source Type 15.14.2.2. By Production Type 15.14.2.3. By Application 15.14.2.4. By End-use 15.15. Indonesia 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2021 15.15.2.1. By Source Type 15.15.2.2. By Production Type 15.15.2.3. By Application 15.15.2.4. By End-use 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2021 15.16.2.1. By Source Type 15.16.2.2. By Production Type 15.16.2.3. By Application 15.16.2.4. By End-use 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2021 15.17.2.1. By Source Type 15.17.2.2. By Production Type 15.17.2.3. By Application 15.17.2.4. By End-use 15.18. GCC Countries 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2021 15.18.2.1. By Source Type 15.18.2.2. By Production Type 15.18.2.3. By Application 15.18.2.4. By End-use 15.19. South Africa 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2021 15.19.2.1. By Source Type 15.19.2.2. By Production Type 15.19.2.3. By Application 15.19.2.4. By End-use 15.20. Israel 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2021 15.20.2.1. By Source Type 15.20.2.2. By Production Type 15.20.2.3. By Application 15.20.2.4. By End-use 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Source Type 16.3.3. By Production Type 16.3.4. By Application 16.3.5. By End-use 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Novartis AG 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Pfizer Inc. 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. GlaxoSmithKline plc 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Amgen Inc. 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Merck & Co., Inc. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Daiichi Sankyo Company, Limited 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Abbott Laboratories 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. AstraZeneca plc 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Eli Lilly And Company 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Johnson & Johnson Services, Inc. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.11. Bayer AG 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 17.1.12. Bristol Myers Squibb 17.1.12.1. Overview 17.1.12.2. Product Portfolio 17.1.12.3. Profitability by Market Segments 17.1.12.4. Sales Footprint 17.1.12.5. Strategy Overview 17.1.12.5.1. Marketing Strategy 17.1.13. F. Hoffman-La Roche Ltd. 17.1.13.1. Overview 17.1.13.2. Product Portfolio 17.1.13.3. Profitability by Market Segments 17.1.13.4. Sales Footprint 17.1.13.5. Strategy Overview 17.1.13.5.1. Marketing Strategy 17.1.14. Viatris Inc. 17.1.14.1. Overview 17.1.14.2. Product Portfolio 17.1.14.3. Profitability by Market Segments 17.1.14.4. Sales Footprint 17.1.14.5. Strategy Overview 17.1.14.5.1. Marketing Strategy 17.1.15. Biogen Inc. 17.1.15.1. Overview 17.1.15.2. Product Portfolio 17.1.15.3. Profitability by Market Segments 17.1.15.4. Sales Footprint 17.1.15.5. Strategy Overview 17.1.15.5.1. Marketing Strategy 17.1.16. Thermo Fisher Scientific, Inc. 17.1.16.1. Overview 17.1.16.2. Product Portfolio 17.1.16.3. Profitability by Market Segments 17.1.16.4. Sales Footprint 17.1.16.5. Strategy Overview 17.1.16.5.1. Marketing Strategy 17.1.17. Novo Nordisk A/S 17.1.17.1. Overview 17.1.17.2. Product Portfolio 17.1.17.3. Profitability by Market Segments 17.1.17.4. Sales Footprint 17.1.17.5. Strategy Overview 17.1.17.5.1. Marketing Strategy 17.1.18. Sanofi S.A. 17.1.18.1. Overview 17.1.18.2. Product Portfolio 17.1.18.3. Profitability by Market Segments 17.1.18.4. Sales Footprint 17.1.18.5. Strategy Overview 17.1.18.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Monoclonal Antibodies Market Value (US$ Million) Forecast by Region, 2017 to 2032 Table 2: Global Monoclonal Antibodies Market Value (US$ Million) Forecast by Source Type, 2017 to 2032 Table 3: Global Monoclonal Antibodies Market Value (US$ Million) Forecast by Production Type, 2017 to 2032 Table 4: Global Monoclonal Antibodies Market Value (US$ Million) Forecast by Application , 2017 to 2032 Table 5: Global Monoclonal Antibodies Market Value (US$ Million) Forecast by End-use, 2017 to 2032 Table 6: North America Monoclonal Antibodies Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 7: North America Monoclonal Antibodies Market Value (US$ Million) Forecast by Source Type, 2017 to 2032 Table 8: North America Monoclonal Antibodies Market Value (US$ Million) Forecast by Production Type, 2017 to 2032 Table 9: North America Monoclonal Antibodies Market Value (US$ Million) Forecast by Application , 2017 to 2032 Table 10: North America Monoclonal Antibodies Market Value (US$ Million) Forecast by End-use, 2017 to 2032 Table 11: Latin America Monoclonal Antibodies Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 12: Latin America Monoclonal Antibodies Market Value (US$ Million) Forecast by Source Type, 2017 to 2032 Table 13: Latin America Monoclonal Antibodies Market Value (US$ Million) Forecast by Production Type, 2017 to 2032 Table 14: Latin America Monoclonal Antibodies Market Value (US$ Million) Forecast by Application , 2017 to 2032 Table 15: Latin America Monoclonal Antibodies Market Value (US$ Million) Forecast by End-use, 2017 to 2032 Table 16: Europe Monoclonal Antibodies Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 17: Europe Monoclonal Antibodies Market Value (US$ Million) Forecast by Source Type, 2017 to 2032 Table 18: Europe Monoclonal Antibodies Market Value (US$ Million) Forecast by Production Type, 2017 to 2032 Table 19: Europe Monoclonal Antibodies Market Value (US$ Million) Forecast by Application , 2017 to 2032 Table 20: Europe Monoclonal Antibodies Market Value (US$ Million) Forecast by End-use, 2017 to 2032 Table 21: Asia Pacific Monoclonal Antibodies Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 22: Asia Pacific Monoclonal Antibodies Market Value (US$ Million) Forecast by Source Type, 2017 to 2032 Table 23: Asia Pacific Monoclonal Antibodies Market Value (US$ Million) Forecast by Production Type, 2017 to 2032 Table 24: Asia Pacific Monoclonal Antibodies Market Value (US$ Million) Forecast by Application , 2017 to 2032 Table 25: Asia Pacific Monoclonal Antibodies Market Value (US$ Million) Forecast by End-use, 2017 to 2032 Table 26: MEA Monoclonal Antibodies Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 27: MEA Monoclonal Antibodies Market Value (US$ Million) Forecast by Source Type, 2017 to 2032 Table 28: MEA Monoclonal Antibodies Market Value (US$ Million) Forecast by Production Type, 2017 to 2032 Table 29: MEA Monoclonal Antibodies Market Value (US$ Million) Forecast by Application , 2017 to 2032 Table 30: MEA Monoclonal Antibodies Market Value (US$ Million) Forecast by End-use, 2017 to 2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Monoclonal Antibodies Market Value (US$ Million) by Source Type, 2022 to 2032 Figure 2: Global Monoclonal Antibodies Market Value (US$ Million) by Production Type, 2022 to 2032 Figure 3: Global Monoclonal Antibodies Market Value (US$ Million) by Application, 2022 to 2032 Figure 4: Global Monoclonal Antibodies Market Value (US$ Million) by End-use, 2022 to 2032 Figure 5: Global Monoclonal Antibodies Market Value (US$ Million) by Region, 2022 to 2032 Figure 6: Global Monoclonal Antibodies Market Value (US$ Million) Analysis by Region, 2017 to 2032 Figure 7: Global Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Region, 2022 to 2032 Figure 8: Global Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032 Figure 9: Global Monoclonal Antibodies Market Value (US$ Million) Analysis by Source Type, 2017 to 2032 Figure 10: Global Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Source Type, 2022 to 2032 Figure 11: Global Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Source Type, 2022 to 2032 Figure 12: Global Monoclonal Antibodies Market Value (US$ Million) Analysis by Production Type, 2017 to 2032 Figure 13: Global Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Production Type, 2022 to 2032 Figure 14: Global Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Production Type, 2022 to 2032 Figure 15: Global Monoclonal Antibodies Market Value (US$ Million) Analysis by Application, 2017 to 2032 Figure 16: Global Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Application , 2022 to 2032 Figure 17: Global Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032 Figure 18: Global Monoclonal Antibodies Market Value (US$ Million) Analysis by End-use, 2017 to 2032 Figure 19: Global Monoclonal Antibodies Market Value Share (%) and BPS Analysis by End-use, 2022 to 2032 Figure 20: Global Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by End-use, 2022 to 2032 Figure 21: Global Monoclonal Antibodies Market Attractiveness by Source Type, 2022 to 2032 Figure 22: Global Monoclonal Antibodies Market Attractiveness by Production Type, 2022 to 2032 Figure 23: Global Monoclonal Antibodies Market Attractiveness by Application, 2022 to 2032 Figure 24: Global Monoclonal Antibodies Market Attractiveness by End-use, 2022 to 2032 Figure 25: Global Monoclonal Antibodies Market Attractiveness by Region, 2022 to 2032 Figure 26: North America Monoclonal Antibodies Market Value (US$ Million) by Source Type, 2022 to 2032 Figure 27: North America Monoclonal Antibodies Market Value (US$ Million) by Production Type, 2022 to 2032 Figure 28: North America Monoclonal Antibodies Market Value (US$ Million) by Application, 2022 to 2032 Figure 29: North America Monoclonal Antibodies Market Value (US$ Million) by End-use, 2022 to 2032 Figure 30: North America Monoclonal Antibodies Market Value (US$ Million) by Country, 2022 to 2032 Figure 31: North America Monoclonal Antibodies Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 32: North America Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 33: North America Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 34: North America Monoclonal Antibodies Market Value (US$ Million) Analysis by Source Type, 2017 to 2032 Figure 35: North America Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Source Type, 2022 to 2032 Figure 36: North America Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Source Type, 2022 to 2032 Figure 37: North America Monoclonal Antibodies Market Value (US$ Million) Analysis by Production Type, 2017 to 2032 Figure 38: North America Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Production Type, 2022 to 2032 Figure 39: North America Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Production Type, 2022 to 2032 Figure 40: North America Monoclonal Antibodies Market Value (US$ Million) Analysis by Application, 2017 to 2032 Figure 41: North America Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Application, 2022 to 2032 Figure 42: North America Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032 Figure 43: North America Monoclonal Antibodies Market Value (US$ Million) Analysis by End-use, 2017 to 2032 Figure 44: North America Monoclonal Antibodies Market Value Share (%) and BPS Analysis by End-use, 2022 to 2032 Figure 45: North America Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by End-use, 2022 to 2032 Figure 46: North America Monoclonal Antibodies Market Attractiveness by Source Type, 2022 to 2032 Figure 47: North America Monoclonal Antibodies Market Attractiveness by Production Type, 2022 to 2032 Figure 48: North America Monoclonal Antibodies Market Attractiveness by Application, 2022 to 2032 Figure 49: North America Monoclonal Antibodies Market Attractiveness by End-use, 2022 to 2032 Figure 50: North America Monoclonal Antibodies Market Attractiveness by Country, 2022 to 2032 Figure 51: Latin America Monoclonal Antibodies Market Value (US$ Million) by Source Type, 2022 to 2032 Figure 52: Latin America Monoclonal Antibodies Market Value (US$ Million) by Production Type, 2022 to 2032 Figure 53: Latin America Monoclonal Antibodies Market Value (US$ Million) by Application, 2022 to 2032 Figure 54: Latin America Monoclonal Antibodies Market Value (US$ Million) by End-use, 2022 to 2032 Figure 55: Latin America Monoclonal Antibodies Market Value (US$ Million) by Country, 2022 to 2032 Figure 56: Latin America Monoclonal Antibodies Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 57: Latin America Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 58: Latin America Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 59: Latin America Monoclonal Antibodies Market Value (US$ Million) Analysis by Source Type, 2017 to 2032 Figure 60: Latin America Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Source Type, 2022 to 2032 Figure 61: Latin America Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Source Type, 2022 to 2032 Figure 62: Latin America Monoclonal Antibodies Market Value (US$ Million) Analysis by Production Type, 2017 to 2032 Figure 63: Latin America Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Production Type, 2022 to 2032 Figure 64: Latin America Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Production Type, 2022 to 2032 Figure 65: Latin America Monoclonal Antibodies Market Value (US$ Million) Analysis by Application, 2017 to 2032 Figure 66: Latin America Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Application, 2022 to 2032 Figure 67: Latin America Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032 Figure 68: Latin America Monoclonal Antibodies Market Value (US$ Million) Analysis by End-use, 2017 to 2032 Figure 69: Latin America Monoclonal Antibodies Market Value Share (%) and BPS Analysis by End-use, 2022 to 2032 Figure 70: Latin America Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by End-use, 2022 to 2032 Figure 71: Latin America Monoclonal Antibodies Market Attractiveness by Source Type, 2022 to 2032 Figure 72: Latin America Monoclonal Antibodies Market Attractiveness by Production Type, 2022 to 2032 Figure 73: Latin America Monoclonal Antibodies Market Attractiveness by Application, 2022 to 2032 Figure 74: Latin America Monoclonal Antibodies Market Attractiveness by End-use, 2022 to 2032 Figure 75: Latin America Monoclonal Antibodies Market Attractiveness by Country, 2022 to 2032 Figure 76: Europe Monoclonal Antibodies Market Value (US$ Million) by Source Type, 2022 to 2032 Figure 77: Europe Monoclonal Antibodies Market Value (US$ Million) by Production Type, 2022 to 2032 Figure 78: Europe Monoclonal Antibodies Market Value (US$ Million) by Application, 2022 to 2032 Figure 79: Europe Monoclonal Antibodies Market Value (US$ Million) by End-use, 2022 to 2032 Figure 80: Europe Monoclonal Antibodies Market Value (US$ Million) by Country, 2022 to 2032 Figure 81: Europe Monoclonal Antibodies Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 82: Europe Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 83: Europe Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 84: Europe Monoclonal Antibodies Market Value (US$ Million) Analysis by Source Type, 2017 to 2032 Figure 85: Europe Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Source Type, 2022 to 2032 Figure 86: Europe Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Source Type, 2022 to 2032 Figure 87: Europe Monoclonal Antibodies Market Value (US$ Million) Analysis by Production Type, 2017 to 2032 Figure 88: Europe Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Production Type, 2022 to 2032 Figure 89: Europe Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Production Type, 2022 to 2032 Figure 90: Europe Monoclonal Antibodies Market Value (US$ Million) Analysis by Application, 2017 to 2032 Figure 91: Europe Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Application, 2022 to 2032 Figure 92: Europe Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032 Figure 93: Europe Monoclonal Antibodies Market Value (US$ Million) Analysis by End-use, 2017 to 2032 Figure 94: Europe Monoclonal Antibodies Market Value Share (%) and BPS Analysis by End-use, 2022 to 2032 Figure 95: Europe Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by End-use, 2022 to 2032 Figure 96: Europe Monoclonal Antibodies Market Attractiveness by Source Type, 2022 to 2032 Figure 97: Europe Monoclonal Antibodies Market Attractiveness by Production Type, 2022 to 2032 Figure 98: Europe Monoclonal Antibodies Market Attractiveness by Application, 2022 to 2032 Figure 99: Europe Monoclonal Antibodies Market Attractiveness by End-use, 2022 to 2032 Figure 100: Europe Monoclonal Antibodies Market Attractiveness by Country, 2022 to 2032 Figure 101: Asia Pacific Monoclonal Antibodies Market Value (US$ Million) by Source Type, 2022 to 2032 Figure 102: Asia Pacific Monoclonal Antibodies Market Value (US$ Million) by Production Type, 2022 to 2032 Figure 103: Asia Pacific Monoclonal Antibodies Market Value (US$ Million) by Application, 2022 to 2032 Figure 104: Asia Pacific Monoclonal Antibodies Market Value (US$ Million) by End-use, 2022 to 2032 Figure 105: Asia Pacific Monoclonal Antibodies Market Value (US$ Million) by Country, 2022 to 2032 Figure 106: Asia Pacific Monoclonal Antibodies Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 107: Asia Pacific Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 108: Asia Pacific Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 109: Asia Pacific Monoclonal Antibodies Market Value (US$ Million) Analysis by Source Type, 2017 to 2032 Figure 110: Asia Pacific Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Source Type, 2022 to 2032 Figure 111: Asia Pacific Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Source Type, 2022 to 2032 Figure 112: Asia Pacific Monoclonal Antibodies Market Value (US$ Million) Analysis by Production Type, 2017 to 2032 Figure 113: Asia Pacific Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Production Type, 2022 to 2032 Figure 114: Asia Pacific Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Production Type, 2022 to 2032 Figure 115: Asia Pacific Monoclonal Antibodies Market Value (US$ Million) Analysis by Application, 2017 to 2032 Figure 116: Asia Pacific Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Application, 2022 to 2032 Figure 117: Asia Pacific Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032 Figure 118: Asia Pacific Monoclonal Antibodies Market Value (US$ Million) Analysis by End-use, 2017 to 2032 Figure 119: Asia Pacific Monoclonal Antibodies Market Value Share (%) and BPS Analysis by End-use, 2022 to 2032 Figure 120: Asia Pacific Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by End-use, 2022 to 2032 Figure 121: Asia Pacific Monoclonal Antibodies Market Attractiveness by Source Type, 2022 to 2032 Figure 122: Asia Pacific Monoclonal Antibodies Market Attractiveness by Production Type, 2022 to 2032 Figure 123: Asia Pacific Monoclonal Antibodies Market Attractiveness by Application, 2022 to 2032 Figure 124: Asia Pacific Monoclonal Antibodies Market Attractiveness by End-use, 2022 to 2032 Figure 125: Asia Pacific Monoclonal Antibodies Market Attractiveness by Country, 2022 to 2032 Figure 126: Middle East & Africa Monoclonal Antibodies Market Value (US$ Million) by Source Type, 2022 to 2032 Figure 127: Middle East & Africa Monoclonal Antibodies Market Value (US$ Million) by Production Type, 2022 to 2032 Figure 128: Middle East & Africa Monoclonal Antibodies Market Value (US$ Million) by Application, 2022 to 2032 Figure 129: Middle East & Africa Monoclonal Antibodies Market Value (US$ Million) by End-use, 2022 to 2032 Figure 130: Middle East & Africa Monoclonal Antibodies Market Value (US$ Million) by Country, 2022 to 2032 Figure 131: Middle East & Africa Monoclonal Antibodies Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 132: Middle East & Africa Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 133: Middle East & Africa Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 134: Middle East & Africa Monoclonal Antibodies Market Value (US$ Million) Analysis by Source Type, 2017 to 2032 Figure 135: Middle East & Africa Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Source Type, 2022 to 2032 Figure 136: Middle East & Africa Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Source Type, 2022 to 2032 Figure 137: Middle East & Africa Monoclonal Antibodies Market Value (US$ Million) Analysis by Production Type, 2017 to 2032 Figure 138: Middle East & Africa Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Production Type, 2022 to 2032 Figure 139: Middle East & Africa Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Production Type, 2022 to 2032 Figure 140: Middle East & Africa Monoclonal Antibodies Market Value (US$ Million) Analysis by Application, 2017 to 2032 Figure 141: Middle East & Africa Monoclonal Antibodies Market Value Share (%) and BPS Analysis by Application, 2022 to 2032 Figure 142: Middle East & Africa Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032 Figure 143: Middle East & Africa Monoclonal Antibodies Market Value (US$ Million) Analysis by End-use, 2017 to 2032 Figure 144: Middle East & Africa Monoclonal Antibodies Market Value Share (%) and BPS Analysis by End-use, 2022 to 2032 Figure 145: Middle East & Africa Monoclonal Antibodies Market Y-o-Y Growth (%) Projections by End-use, 2022 to 2032 Figure 146: Middle East & Africa Monoclonal Antibodies Market Attractiveness by Source Type, 2022 to 2032 Figure 147: Middle East & Africa Monoclonal Antibodies Market Attractiveness by Production Type, 2022 to 2032 Figure 148: Middle East & Africa Monoclonal Antibodies Market Attractiveness by Application, 2022 to 2032 Figure 149: Middle East & Africa Monoclonal Antibodies Market Attractiveness by End-use, 2022 to 2032 Figure 150: Middle East & Africa Monoclonal Antibodies Market Attractiveness by Country, 2022 to 2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
